VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
VistaGen Therapeutics, Inc. (VTGN) is a Biotechnology company based in US with a market capitalization of $7.7M. Revenue declined 54.3% year-over-year and free cash flow was negative at -$42.3M. This page tracks VTGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 48 employees · IPO Jun 21, 2011
Valuation
Valuation & price
$0.62as of May 17, 2026· -87.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.22
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$7.7M
Market cap
-54.3%
Revenue growth (YoY)
100.0%
Gross margin
-$42.3M
Free cash flow (USD)
-$79M
Net debt
Net cash position
58.7%
Share dilution
1/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: Jun 15, 2026 (EPS $-0.37)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 30, 2026Filing
Phase 3 Trial Results
- 8-K eventJun 17, 2026Filing
Director Not Standing for Re-election
- 8-K eventJun 15, 2026Filing
Fiscal Year 2026 Results
- Annual reportJun 15, 2026Filing
10-K Filed
- 8-K eventJun 9, 2026Filing
Clinical Program Update
- 8-K eventMay 19, 2026Filing
Indemnification Agreement
- 8-K eventMay 12, 2026Filing
Positive Study Results
- 8-K eventMay 8, 2026Filing
Clinical Trial Update
- 8-K eventApr 28, 2026Filing
FDA Approval Received
- 8-K eventApr 13, 2026Filing
Stock Option Grants
Questions
Frequently asked questions
What is VistaGen Therapeutics, Inc.'s market cap?
VistaGen Therapeutics, Inc. (VTGN) has a market capitalization of $7.7M.
What is VTGN's P/E ratio?
A meaningful P/E ratio is not available for VTGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is VTGN's price-to-book (P/B) ratio?
VTGN trades at 0.22 times book value per share.
When did VistaGen Therapeutics, Inc. last report earnings?
VTGN last reported earnings on June 15, 2026; the next date is not yet scheduled.
Are insiders buying VTGN stock?
SEC Form 4 filings show no open-market insider buys at VistaGen Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.